Cancer Clinical Pharmacology
Jan H. M. Schellens, Howard L. McLeod, David R. Newell
OUP Oxford, May 5, 2005 - Medical - 267 pages
Cancer Clinical Pharmacology provides a comprehensive account of the scientific basis of anti-cancer therapy in patients with solid tumours and haematological malignancies. An international group of experts have brought together information on the basic principles of pharmacology and tumour biology, bioanalytical aspects, pharmacokinetics, and the pharmacodynamics of anti-cancer agents. The clinical pharmacology of individual anti-cancer agents are covered, including the most important recently registered novel anti-cancer drugs. This book will prove an invaluable source of information for all trainees in oncology, haematology and internal medicine. Since cancer clinical pharmacology is a vast subject this book will be useful for all individuals involved in cancer pharmacology such as nurses, pharmacists, general pharmacologists, and cancer scientists.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Bioanalytical methods for anticancer drugs
Principles of pharmacokinetics
Clinical implications and mechanisms of variability in the response to anticancer agents
Drug development and study design
Purine analogs and antifolates
Topoisomerase I targeting agents
focus on imatinib and gefitinib
Antiendocrine drugs used in cancer treatment
The clinical application of tumour biology
activity adducts aminoglutethimide analogues anthracyclines anticancer drugs antitumour ara-C aromatase inhibitors assay Beijnen JH bioavailability Biochem blood bolus breast cancer camptothecin Cancer Chemother Pharmacol cancer patients capecitabine carboplatin cell lines cellular chemotherapy Chromatogr cisplatin cladribine clearance Clin Cancer Res Clin Oncol correlation cytotoxicity daunorubicin docetaxel dose doxorubicin effects EGFR elimination enzyme epirubicin etoposide excretion fludarabine gefitinib gene growth factor half-life hepatic high-dose HPLC idarubicin ifosfamide imatinib increased infusion inhibition interactions intracellular intravenous irinotecan kinetics lactone leukemia levels liquid chromatography liver Mechanism of action Mechanisms of resistance melphalan metabolism metabolites metastatic methotrexate mutations ng/ml oral administration paclitaxel pathways patients with advanced pharmacodynamic pharmacokinetics pharmacological phase plasma plasma concentrations platinum preclinical Proc protein binding receptor renal response samples tamoxifen target taxanes teniposide therapeutic therapy thiotepa tion tissue topo topoisomerase topotecan toxicity treatment tyrosine kinase urine vinblastine vinca alkaloids vincristine vinorelbine vitro vivo